Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), in September 1993.

Jane has many years of experience of antibody engineering and currently leads the Biosuperiors team and the MedImmune Cambridge R&D site. She originated several key publications and patents, and also made a significant contribution to the discovery and development of marketed drugs and more than 40 clinical candidates.

Prior to joining CAT, Jane obtained a First Class degree in Natural Sciences (Biochemistry) from the University of Cambridge and completed a PhD at the John Innes Centre for Plant Science Research in Norwich. This was followed by a postdoctoral position at Rutgers University, New Jersey before moving into medical research through a British Heart Foundation Postdoctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.

In 2010, Jane won the Institute of Directors’ East of England Business Woman of the Year Award in recognition of her contribution to the successful integration and development of CAT and MedImmune in Cambridge.

Jane is a member of the Board of the BioIndustry Association, a member of the Board of Babraham Bioscience Technologies and a member of the UK Medical Research Council Industry Grant Award Assessment Panel. She is an editor of both ‘Mab Journal’ and ‘Protein Engineering Design and Selection’.

I love working for MedImmune because of the passion of our people for great science and our ability to turn this into life-improving drugs.

Jane Osbourn


Vice-President Research and Development, MedImmune Cambridge


IND filing of Medi4276, MedImmune’s first bispecific antibody-directed conjugate – a Biosuperior drug candidate with real potential to help certain types of breast cancer patients (2015)


Presenting on behalf of AstraZeneca to the Cambridge City Council Planning Committee as part of the planning process for AstraZeneca’s new HQ building at the Cambridge BioMedical Campus – an opportunity to learn about engineering, sustainability, and the planning process and to explain the role of in vivo studies in supporting the delivery of medicines to patients (2015)


Presenting the keynote talk at IBC’s Antibody Engineering and Therapeutics conference in California (2013)

  Featured publications

Generation of related human scFv antibodies panel

Generation of a panel of related human scFv antibodies with high affinities for human CEA. Osbourn, J.K., Fields, A., Wilton, J., Derbyshire, E., Earnshaw, J.C., Jones, P.T., Allen, D and McCafferty, J. Immunotechnology 1996: 2; 181-196

Directed selection of MIP-1 neutralising CCR5 antibodies

Directed selection of MIP-1 neutralising CCR5 antibodies from a phage display human antibody library. Osbourn, J.K., Earnshaw, J.C., Johnson, K.S., Parmentier, M., Timmermans, V. and McCafferty, J. Nat. Biotech. 1998: 16; 778-781

Generating human antibodies for autoimmune disease

Current methods for the generation of human antibodies for the treatment of autoimmune disease. Osbourn, J.K., Jermutus, L., Duncan, A.R. Drug Discovery Today 2003: 8(18) 845-851.


One of top 50 UK women in BioBusiness (BioBeat; 2014)


East of England Business Woman of the Year Award (IOD; 2010)


Mosseri Prize for Biological Sciences (University of Cambridge; 1987)